Obesity, serious mental illness and antipsychotic drugs

Diabetes, Obesity and Metabolism

Volumn 11, Issue 7, 2009, Pages 665-679

  Holt, Richard I G ^a   Peveler, Robert C ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Aetiology; Antipsychotic; Bipolar illness; Obesity; Schizophrenia

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BETA 3 ADRENERGIC RECEPTOR; BETAHISTINE; CHLORPROMAZINE; CLOZAPINE; CYTOKINE; GHRELIN; GLUCOCORTICOID; HALOPERIDOL; HISTAMINE H1 RECEPTOR; HORMONE; LEPTIN; MELANOCORTIN 4 RECEPTOR; MIFEPRISTONE; NEUROLEPTIC AGENT; NEUROPEPTIDE Y; NEUROTRANSMITTER; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 2C RECEPTOR; ZIPRASIDONE;

APPETITE; BINDING AFFINITY; BODY WEIGHT; BRAIN CORTEX; CENTRAL NERVOUS SYSTEM FUNCTION; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; ENERGY CONSUMPTION; ENVIRONMENTAL FACTOR; FAT CONTENT; FEEDING BEHAVIOR; FOOD PREFERENCE; GASTROINTESTINAL TRACT FUNCTION; GENETIC PREDISPOSITION; HORMONE ACTION; HUMAN; HYPOTHALAMUS; LIMBIC SYSTEM; LIPID METABOLISM; LONG TERM CARE; MENTAL DISEASE; NEUROENDOCRINE SYSTEM; NONHUMAN; OBESITY; PATHOGENESIS; PATIENT COMPLIANCE; PROTEIN PROTEIN INTERACTION; PSYCHOSIS; REVIEW; SATIETY; SCHIZOPHRENIA; SEDATION; SERIOUS MENTAL DISEASE; SIDE EFFECT; SIGNAL TRANSDUCTION; THIRST; WEIGHT CONTROL; WEIGHT GAIN;

EID: 70349194825     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01038.x     Document Type: Review

References (185)

1. James PT, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 2004, 11:3-8.
2. Visscher TL, Seidell JC. The public health impact of obesity. Annu Rev Public Health 2001, 22:355-375.
3. Silventoinen K, Sans S, Tolonen H. Trends in obesity and energy supply in the WHO MONICA project. Int J Obes Relat Metab Disord 2004, 28:710-718.
4. Dickerson FB, Brown CH, Kreyenbuhl JA. Obesity among individuals with serious mental illness. Acta Psychiatr Scand 2006, 113:306-313.
5. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res 2002, 55:277-284.
6. McEvoy JP, Meyer JM, Goff DC. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
7. Pendlebury J, Bushe CJ, Wildgust HJ, Holt RI. Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatr Scand 2007, 115:286-294.
8. Theisen FM, Linden A, Geller F. Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. J Psychiatr Res 2001, 35:339-345.
9. Kraepelin E, Barkley RM. Dementia praecox and paraphrenia 1919, trans, ed, Edinburgh, E & S Livingstone
10. Green AI, Lieberman JA, Hamer RM. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 2006, 86:234-243.
11. Lieberman JA, Phillips M, Gu H. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003, 28:995-1003.
12. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999, 29:697-701.
13. Brugha TS, Wing JK, Smith BL. Physical health of the long-term mentally ill in the community. Is there unmet need?. Br J Psychiatry 1989, 155:777-781.
14. Kendrick T. Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness. Br J Psychiatry 1996, 169:733-739.
15. Allison DB, Fontaine KR, Heo M. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999, 60:215-220.
16. Morgan DB, Hullin RP. The body composition of the chronic mentally ill. Hum Nutr Clin Nutr 1982, 36:439-448.
17. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002, 26:137-141.
18. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004, 184:58-62.
19. van Nimwegen LJ, Storosum JG, Blumer RM. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 2008, 93:572-577.
20. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995, 122:481-486.
21. Wynne K, Stanley S, Bloom S. The gut and regulation of body weight. J Clin Endocrinol Metab 2004, 89:2576-2582.
22. Allison DB, Kaprio J, Korkeila M, Koskenvuo M, Neale MC, Hayakawa K. The heritability of body mass index among an international sample of monozygotic twins reared apart. Int J Obes Relat Metab Disord 1996, 20:501-506.
23. Hebebrand J, Sommerlad C, Geller F, Gorg T, Hinney A. The genetics of obesity: practical implications. Int J Obes Relat Metab Disord 2001, 25(Suppl. 1):S10-S18.
24. Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. Behav Genet 1997, 27:325-351.
25. Farooqi S, O'Rahilly S. Genetics of obesity in humans. Endocr Rev 2006, 27:710-718.
26. Frayling TM, Timpson NJ, Weedon MN. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007, 316:889-894.
27. Loos RJ, Lindgren CM, Li S. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008, 40:768-775.
28. Konturek PC, Konturek JW, Czesnikiewicz-Guzik M, Brzozowski T, Sito E, Konturek SJ. Neuro-hormonal control of food intake: basic mechanisms and clinical implications. J Physiol Pharmacol 2005, 56(Suppl. 6):5-25.
29. Meister B. Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weight. Physiol Behav 2007, 92:263-271.
30. Qian S, Chen H, Weingarth D. Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice. Mol Cell Biol 2002, 22:5027-5035.
31. Huszar D, Lynch CA, Fairchild-Huntress V. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997, 88:131-141.
32. Naslund E, Hellstrom PM. Appetite signaling: from gut peptides and enteric nerves to brain. Physiol Behav 2007, 92:256-262.
33. Wren AM, Seal LJ, Cohen MA. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001, 86.
34. Nakazato M, Murakami N, Date Y. A role for ghrelin in the central regulation of feeding. Nature 2001, 409:194-198.
35. Badman MK, Flier JS. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 2007, 132:2103-2115.
36. Montague CT, Farooqi IS, Whitehead JP. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997, 387:903-908.
37. Clement K, Vaisse C, Lahlou N. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998, 392:398-401.
38. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000, 407:908-913.
39. Blundell JE, Finlayson G. Is susceptibility to weight gain characterized by homeostatic or hedonic risk factors for overconsumption?. Physiol Behav 2004, 82:21-25.
40. Wang GJ, Volkow ND, Logan J. Brain dopamine and obesity. Lancet 2001, 357:354-357.
41. Elman I, Borsook D, Lukas SE. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 2006, 31:2091-2120.
42. Anthony K, Reed LJ, Dunn JT. Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: the cerebral basis for impaired control of food intake in metabolic syndrome?. Diabetes 2006, 55:2986-2992.
43. Kunos G. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system?. Am J Med 2007, 120(9 Suppl. 1):S18-S24.
44. McCreadie R, Macdonald E, Blacklock C. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study. BMJ 1998, 317:784-785.
45. Kilbourne AM, Rofey DL, McCarthy JF, Post EP, Welsh D, Blow FC. Nutrition and exercise behavior among patients with bipolar disorder. Bipolar Disord 2007, 9:443-452.
46. Godfrey R, Julien M. Urbanisation and health. Clin Med 2005, 5:137-141.
47. O'Donovan MC, Williams NM, Owen MJ. Recent advances in the genetics of schizophrenia. Hum Mol Genet 2003, 12:R125-R133.
48. Gough SC, O' Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?. J Psychopharmacol 2005, 19(6 Suppl):47-55.
49. Jacobson P, Rankinen T, Tremblay A, Perusse L, Chagnon YC, Bouchard C. Resting metabolic rate and respiratory quotient: results from a genome-wide scan in the Quebec Family Study. Am J Clin Nutr 2006, 84:1527-1533.
50. Nilsson BM, Forslund AH, Olsson RM, Hambraeus L, Wiesel FA. Differences in resting energy expenditure and body composition between patients with schizophrenia and healthy controls. Acta Psychiatr Scand 2006, 114:27-35.
51. Sharpe JK, Byrne NM, Stedman TJ, Hills AP. Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication. J Am Diet Assoc 2005, 105:612-615.
52. Soreca I, Mauri M, Castrogiovanni S, Simoncini M, Cassano GB. Measured and expected resting energy expenditure in patients with bipolar disorder on maintenance treatment. Bipolar Disord 2007, 9:784-788.
53. Sayer AA, Cooper C. Fetal programming of body composition and musculoskeletal development. Early Hum Dev 2005, 81:735-744.
54. Sayer AA, Syddall HE, Dennison EM. Birth weight, weight at 1 y of age, and body composition in older men: findings from the Hertfordshire Cohort Study. Am J Clin Nutr 2004, 80:199-203.
55. Rogers I. The influence of birthweight and intrauterine environment on adiposity and fat distribution in later life. Int J Obes Relat Metab Disord 2003, 27:755-777.
56. Susser ES, Lin SP. Schizophrenia after prenatal exposure to the Dutch Hunger Winter of 1944-1945. Arch Gen Psychiatry 1992, 49:983-988.
57. Nieuwenhuizen AG, Rutters F. The hypothalamic-pituitary-adrenal-axis in the regulation of energy balance. Physiol Behav 2008, 94:169-177.
58. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 1996, 20:291-302.
59. Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989, 321:1797-1803.
60. Dinan T, Peveler R, Holt R. Understanding schizophrenia and diabetes. Hosp Med 2004, 65:485-488.
61. Venkatasubramanian G, Chittiprol S, Neelakantachar N. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 2007, 164:1557-1560.
62. Huber TJ, Tettenborn C, Leifke E, Emrich HM. Sex hormones in psychotic men. Psychoneuroendocrinology 2005, 30:111-114.
63. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998, 83:847-850.
64. Justo D. Smoldering systemic inflammation: a link between schizophrenia, smoking and obesity. Acta Psychiatr Scand 2006, 113:245-246.
65. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003, 54:317-329.
66. Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher-Svanum H, Siris SG. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 2006, 26:157-162.
67. Peuskens J, De Hert M, Mortimer A. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol 2007, 22:145-152.
68. McQuade RD, Stock E, Marcus R. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004, 65(Suppl. 18):47-56.
69. Breier A, Berg PH, Thakore JH. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005, 162:1879-1887.
70. Beasley CM, Sutton VK, Hamilton SH. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003, 23:582-594.
71. Rosenheck R, Perlick D, Bingham S. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003, 290:2693-2702.
72. Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology 2006, 189:259-266.
73. Tohen M, Greil W, Calabrese JR. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005, 162:1281-1290.
74. Tohen M, Chengappa KN, Suppes T. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004, 184:337-345.
75. McEvoy JP, Lieberman JA, Perkins DO. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007, 164:1050-1060.
76. Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008, 22:547-562.
77. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 2007, 100:395-404.
78. Allison DB, Mentore JL, Heo M. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
79. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005, 19(6 Suppl):16-27.
80. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 2006, 20:293-301.
81. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004, 66:51-57.
82. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005, 25:255-258.
83. Lieberman JA, Stroup TS, McEvoy JP. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
84. Tollefson GD, Beasley CM, Tran PV. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997, 154:457-465.
85. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001, 15:537-551.
86. Lipkovich I, Citrome L, Perlis R. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol 2006, 26:316-320.
87. Isaac M, Isaac M, Holloway F. Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care. Hum Psychopharmacol 2005, 20:207-210.
88. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001, 62:231-238.
89. Ratzoni G, Gothelf D, Brand-Gothelf A. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002, 41:337-343.
90. Lane HY, Liu YC, Huang CL. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006, 26:128-134.
91. Blin O, Micallef J. Antipsychotic-associated weight gain and clinical outcome parameters. J Clin Psychiatry 2001, 62(Suppl. 7):11-21.
92. Lambert M, Haro JM, Novick D. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand 2005, 111:232-243.
93. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001, 62:92-100.
94. Jones B, Basson BR, Walker DJ, Crawford AM, Kinon BJ. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001, 62(Suppl. 2):41-44.
95. Ganguli R, Brar JS, Ayrton Z. Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophr Res 2001, 49:261-267.
96. Tohen M, Kryzhanovskaya L, Carlson G. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007, 164:1547-1556.
97. Frazier JA, Biederman J, Tohen M. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2001, 11:239-250.
98. Tramontina S, Zeni CP, Pheula GF, de Souza CK, Rohde LA. Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial. CNS Spectr 2007, 12:758-762.
99. Expert Consensus Meeting, Dublin, 14-15 April 2005, consensus summary. Metabolic and lifestyle issues and severe mental illness - new connections to well-being. J Psychopharmacol 2005, 19(Suppl):118-122.
100. Clinical guidelines 1 2002, http://www.nice.org.uk, London, Published by the, National Institute for Clinical Excellence, Available from URL, (Accessed 12 February 2008)
101. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601.
102. Muller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006, 7:863-887.
103. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002, 359:2086-2087.
104. Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003, 160:677-679.
105. Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:1021-1028.
106. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005, 15:195-200.
107. Basile VS, Masellis M, De Luca V, Meltzer HY, Kennedy JL. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002, 30:1790-1791.
108. Ellingrod VL, Perry PJ, Ringold JC. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005, 134:76-78.
109. Ellingrod VL, Perry PJ, Lund BC. 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J Clin Psychopharmacol 2002, 22:622-624.
110. Zhang ZJ, Yao ZJ, Mou XD. [Association of -2548G/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent-induced weight gain]. Zhonghua Yi Xue Za Zhi 2003, 83:2119-2123.
111. Ellingrod VL, Bishop JR, Moline J, Lin YC, Miller dD. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol Bull 2007, 40:57-62.
112. Kang SG, Lee HJ, Park YM. Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:160-163.
113. Ryu S, Cho EY, Park T. 759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:673-677.
114. Wang YC, Bai YM, Chen JY, Lin CC, Lai IC, Liou YJ. Polymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gain. J Neural Transm 2005, 112:1463-1468.
115. Wang YC, Bai YM, Chen JY, Lin CC, Lai IC, Liou YJ. C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population. Pharmacogenet Genomics 2005, 15:743-748.
116. Muller DJ, Klempan TA, De Luca V. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 2005, 379:81-89.
117. Musil R, Spellmann I, Riedel M. SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. J Psychiatr Res 2008, 42:963-970.
118. Zhang XY, Zhou DF, Wu GY. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 2008, 33:2200-2205.
119. Goudie AJ, Cooper GD, Halford JC. Antipsychotic-induced weight gain. Diabetes Obes Metab 2005, 7:478-487.
120. Rege S. Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust N Z J Psychiatry 2008, 42:369-381.
121. Kluge M, Schuld A, Himmerich H. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol 2007, 27:662-666.
122. Gebhardt S, Haberhausen M, Krieg JC. Clozapine/olanzapine-induced recurrence or deterioration of binge eating-related eating disorders. J Neural Transm 2007, 114:1091-1095.
123. Masaki T, Yoshimatsu H. The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity. Trends Pharmacol Sci 2006, 27:279-284.
124. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T. Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes 2001, 50:376-384.
125. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T. Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes 2001, 50:385-391.
126. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000, 68:29-39.
127. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008, 13:27-35.
128. Wirshing DA, Wirshing WC, Kysar L. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999, 60:358-363.
129. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 2007, 104:3456-3459.
130. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005, 20:368-378.
131. Goudie AJ, Halford JC, Dovey TM, Cooper GD, Neill JC. H(1)-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28:2209-2211.
132. Kroeze WK, Hufeisen SJ, Popadak BA. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28:519-526.
133. Poyurovsky M, Pashinian A, Levi A, Weizman R, Weizman A. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol 2005, 20:101-103.
134. Dryden S, Frankish HM, Wang Q, Pickavance L, Williams G. The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats. Neuroscience 1996, 72:557-566.
135. Tecott LH, Sun LM, Akana SF. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995, 374:542-546.
136. Huang XF, Han M, Huang X, Zavitsanou K, Deng C. Olanzapine differentially affects 5-HT2Aand2C receptor mRNA expression in the rat brain. Behav Brain Res 2006, 171:355-362.
137. Kirk SL, Cahir M, Reynolds GP. Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus. J Psychopharmacol 2006, 20:577-579.
138. Obuchowicz E, Turchan J. Influence of typical and atypical antipsychotics on neuropeptide Y-like immunoreactivity and NPY mRNA expression in rat striatum. Neuropeptides 1998, 32:473-480.
139. Huang XF, Deng C, Zavitsanou K. Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats. Neuropeptides 2006, 40:213-219.
140. Fadel J, Bubser M, Deutch AY. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 2002, 22:6742-6746.
141. Angelucci F, Aloe L, Iannitelli A, Gruber SH, Mathe AA. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur Neuropsychopharmacol 2005, 15:311-317.
142. Dalal MA, Schuld A, Pollmacher T. Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects. Mol Psychiatry 2003, 8:836-837.
143. Gothelf D, Falk B, Singer P. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002, 159:1055-1057.
144. Engl J, Laimer M, Niederwanger A. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry 2005, 10:1089-1096.
145. Ader M, Kim SP, Catalano KJ. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005, 54:862-871.
146. Sundram S. Cannabis and neurodevelopment: implications for psychiatric disorders. Hum Psychopharmacol 2006, 21:245-254.
147. Lindenmayer JP, Khan A, Eerdekens M, Van Hove I, Kushner S. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2007, 17:138-144.
148. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003, 160:1125-1132.
149. Chawla B, Luxton-Andrew H. Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. Hum Psychopharmacol 2008, 23:211-216.
150. Crocq MA, Guillon MS, Bailey PE, Provost D. Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets. Eur Psychiatry 2007, 22:453-454.
151. Arranz B, San L, Duenas RM. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol 2007, 22:11-15.
152. Reinstein MJ, Sonnenberg JG, Mohan SC, Jones LE, Girard J. Difference in weight change and hypersalivation between FazaClo (clozapine, USP) orally disintegrating tablets and solid oral clozapine tablets 2006, American Psychiatry Association meeting NR575, Toronto May 20-25
153. de Haan L, van Amelsvoort T, Rosien K, Linszen D. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology 2004, 175:389-390.
154. Chue P, Prinzo RS, Binder CE. Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets. Hum Psychopharmacol 2007, 22:307-314.
155. Togo T, Hasegawa K, Miura S. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology 2004, 172:230-232.
156. Palik E, Birkas KD, Faludi G, Karadi I, Cseh K. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 2005, 68(Suppl. 1):S60-S64.
157. Sporn AL, Bobb AJ, Gogtay N. Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. J Am Acad Child Adolesc Psychiatry 2005, 44:925-933.
158. Theisen FM, Gebhardt S, Bromel T. A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 2005, 112:1411-1416.
159. Himmerich H, Fulda S, Kunzel HE. Ghrelin plasma levels during psychopharmacological treatment. Neuropsychobiology 2005, 52:11-16.
160. Popovic V, Doknic M, Maric N. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology 2007, 85:249-256.
161. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000, 61:742-749.
162. Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses - a comparison between different antipsychotic agents. Psychopharmacology 2001, 154:205-212.
163. Eder U, Mangweth B, Ebenbichler C. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 2001, 158:1719-1722.
164. Herran A, Garcia-Unzueta MT, Amado JA, de La Maza MT, Alvarez C, Vazquez-Barquero JL. Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry 2001, 179:59-62.
165. Haupt DW, Luber A, Maeda J, Melson AK, Schweiger JA, Newcomer JW. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology 2005, 30:184-191.
166. Baptista T, Davila A, El FY. Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia. Int Clin Psychopharmacol 2007, 22:205-211.
167. Beebe KL, Block T, Debattista C, Blasey C, Belanoff JK. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Behav Brain Res 2006, 171:225-229.
168. Blessing WW, Zilm A, Ootsuka Y. Clozapine reverses increased brown adipose tissue thermogenesis induced by 3,4-methylene-dioxymethamphetamine and by cold exposure in conscious rats. Neuroscience 2006, 141:2067-2073.
169. Minet-Ringuet J, Even PC, Goubern M, Tome D, de Beaurepaire R. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 2006, 46:254-262.
170. Ota M, Mori K, Nakashima A, Kaneko YS, Takahashi H, Ota A. Resistance to excessive bodyweight gain in risperidone-injected rats. Clin Exp Pharmacol Physiol 2005, 32:279-287.
171. Monda M, Viggiano A, Viggiano A, Fuccio F, De Luca V. Clozapine blocks sympathetic and thermogenic reactions induced by orexin A in rat. Physiol Res 2004, 53:507-513.
172. Levine JA, Schleusner SJ, Jensen MD. Energy expenditure of nonexercise activity. Am J Clin Nutr 2000, 72:1451-1454.
173. Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 2005, 20:183-198.
174. Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004, 65:471-477.
175. Vestri HS, Maianu L, Moellering DR, Garvey WT. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007, 32:765-772.
176. Ferno J, Raeder MB, Vik-Mo AO. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?. Pharmacogenomics J 2005, 5:298-304.
177. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2003, 59:19-27.
178. Holden JM, Holden UP. Weight changes with schizophrenic psychosis and psychotropic drug therapy. Psychosomatics 1970, 11:551-561.
179. Czobor P, Volavka J, Sheitman B. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002, 22:244-251.
180. Procyshyn RM, Wasan KM, Thornton AE. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci 2007, 32:331-338.
181. Zipursky RB, Gu H, Green AI. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005, 187:537-543.
182. Ratner Y, Gibel A, Yorkov V, Ritsner MS. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1401-1409.
183. Malik VS, Schulze MB, Hu FB. Intake of sugar-sweetened beverages and weight gain: a systematic review. Am J Clin Nutr 2006, 84:274-288.
184. Baptista T, Elfakih Y, Uzcategui E. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 2008, 22:477-495.
185. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007, 1.